NCT05192681 2022-01-14Tislelizumab as Cross-line Treatment for Advanced NSCLCFujian Cancer HospitalPhase 2 Unknown35 enrolled
NCT04733521 2021-02-02A Phase 1/2 Study of SC-43 in Combination With CisplatinRaND BiosciencesPhase 1/2 Unknown100 enrolled